Tissue-selective estrogen complexes for postmenopausal women

Maturitas

Volumn 76, Issue 3, 2013, Pages 213-220

  Mirkin, Sebastian ^a   Komm, Barry S ^a  

^a PFIZER INC   (United States)

Author keywords

Bazedoxifene; Osteoporosis; SERMs; TSECs; Vasomotor symptoms; Vulvar vaginal atrophy

Indexed keywords

BAZEDOXIFENE; CARBOXY TERMINAL TELOPEPTIDE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; OSTEOCALCIN; PLACEBO;

AMENORRHEA; BONE DENSITY; BONE TURNOVER; BREAST; CLIMACTERIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPAREUNIA; ENDOMETRIAL THICKNESS; ENDOMETRIUM HYPERPLASIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; MASTALGIA; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SLEEP DISORDER; SLEEP QUALITY; SPINE FRACTURE; TISSUE SELECTIVE ESTROGEN COMPLEX; UTERUS; VAGINA ATROPHY; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VAGINAL PRURITUS; VASOMOTOR DISORDER; VULVA DISEASE;

BAZEDOXIFENE; BMD; BONE MINERAL DENSITY; BZA; CE; CONJUGATED ESTROGENS; EPT; ER; ESTROGEN RECEPTOR; ESTROGEN-PROGESTIN THERAPY; LAS; LASOFOXIFENE; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; MCF-7; MENOPAUSE SYMPTOMS TREATMENT SATISFACTION QUESTIONNAIRE; MENOPAUSE-SPECIFIC QUALITY OF LIFE; MENQOL; MICHIGAN CANCER FOUNDATION-7; MS-TSQ; OSTEOPOROSIS; RALOXIFENE; RLX; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGENS, MENOPAUSE, AND RESPONSE TO THERAPY; SERM; SERMS; SMART; TISSUE SELECTIVE ESTROGEN COMPLEX; TSEC; TSECS; VASOMOTOR SYMPTOMS; VENOUS THROMBOEMBOLIC EVENT; VMS; VTE; VULVAR/VAGINAL ATROPHY; VVA;

BREAST; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SLEEP; UTERUS; VAGINAL DISEASES;

EID: 84887467281     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.06.003     Document Type: Review

References (65)

1. A.H. MacLennan, J.L. Broadbent, S. Lester, and V. Moore Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes Cochrane Database of Systematic Reviews 2004 CD002978
2. E. Weiderpass, H.O. Adami, and J.A. Baron Risk of endometrial cancer following estrogen replacement with and without progestins Journal of the National Cancer Institute 91 1999 1131 1137
3. North American Menopause Society The 2012 hormone therapy position statement of The North American Menopause Society Menopause 19 2012 257 271
4. D.F. Archer Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms Drugs and Aging 27 2010 533 544
5. J.M. Hall, and D.P. McDonnell Selective estrogen receptor modulators: from bench, to bedside, and back again Menopausal Medicine 16 2008 S1 S6
6. R. Kagan The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms Journal of Women's Health (Larchmt) 21 2012 975 981
7. P.D. Miller, A.A. Chines, and C. Christiansen Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study Journal of Bone and Mineral Research 23 2008 525 535
8. S.L. Silverman, C. Christiansen, and H.K. Genant Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial Journal of Bone and Mineral Research 23 2008 1923 1934
9. Y. Kharode, P.V. Bodine, C.P. Miller, C.R. Lyttle, and B.S. Komm The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention Endocrinology 149 2008 6084 6091
10. K.F. Ethun, C.E. Wood, J.M. Cline, T.C. Register, S.E. Appt, and T.B. Clarkson Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model Menopause February 2013 [Epub ahead of print]
11. S. Ronkin, R. Northington, and E. Baracat Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women Obstetrics and Gynecology 105 2005 1397 1404
12. J.V. Pinkerton, D.F. Archer, and W.H. Utian Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 16 2009 1102 1108
13. D.F. Archer, J.V. Pinkerton, and W.H. Utian Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women Menopause 16 2009 1109 1115
14. P.Y. Maximov, T.M. Lee, and V.C. Jordan The discovery and development of Selective Estrogen Receptor Modulators (SERMs) for clinical practice Current Clinical Pharmacology 8 2012 135 155
15. T.J. Berrodin, K.C. Chang, B.S. Komm, L.P. Freedman, and S. Nagpal Differential biochemical and cellular actions of premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination Molecular Endocrinology 23 2009 75 85
16. M. Dey, C.R. Lyttle, and J.H. Pickar Recent insights into the varying activity of estrogens Maturitas 34 Suppl. 2 2000 S25 S33
17. B.S. Komm, F. Vlasseros, R. Samadfam, L. Chouinard, and S.Y. Smith Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats Bone 49 2011 376 386
18. B.J. Peano, J.S. Crabtree, B.S. Komm, R.C. Winneker, and H.A. Harris Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland Endocrinology 150 2009 1897 1903
19. Y. Song, R.J. Santen, J.P. Wang, and W. Yue Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice Endocrinology 153 2012 5706 5715
20. Y. Song, R.J. Santen, J.P. Wang, and W. Yue Inhibitory effects of a bazedoxifene/conjugated equine estrogen combination on human breast cancer cells in vitro Endocrinology 154 2012 656 665
21. S.E. Wardell, D. Kazmin, and D.P. McDonnell Research resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes Molecular Endocrinology 26 2012 1235 1248
22. K.F. Ethun, C.E. Wood, T.C. Register, J.M. Cline, S.E. Appt, and T.B. Clarkson Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys Menopause 19 2012 1242 1252
23. J.S. Lewis-Wambi, H. Kim, R. Curpan, R. Grigg, M.A. Sarker, and V.C. Jordan The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1 Molecular Pharmacology 80 2011 610 620
24. P. Oliva, C. Roncoroni, and E. Radaelli Global profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation Reproduction Science 20 2013 119 128
25. J. Kulak Jr., C. Fischer, B. Komm, and H.S. Taylor Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model Endocrinology 152 2011 3226 3232
26. D.F. Archer, V. Lewis, B.R. Carr, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women Fertility and Sterility 92 2009 1039 1044
27. R. Kagan, R.S. Williams, K. Pan, S. Mirkin, and J.H. Pickar A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women Menopause 17 2010 281 289
28. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertility and Sterility 92 2009 1045 1052
29. R.A. Lobo, J.V. Pinkerton, and M.L. Gass Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile Fertility and Sterility 92 2009 1025 1038
30. S. Mirkin, B.S. Komm, K. Pan, and A.A. Chines Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women Climacteric October 2012 [Epub ahead of print]
31. J.H. Pickar, I.-T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertility and Sterility 92 2009 1018 1024
32. J.V. Pinkerton, W.H. Utian, G.D. Constantine, S. Olivier, and J.H. Pickar Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial Menopause 16 2009 1116 1124
33. W. Utian, H. Yu, J. Bobula, S. Mirkin, S. Olivier, and J.H. Pickar Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women Maturitas 63 2009 329 335
34. G. Bachmann, J. Bobula, and S. Mirkin Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy Climacteric 13 2010 132 140
35. J.A. Harvey, J.V. Pinkerton, E.C. Baracat, H. Shi, A.A. Chines, and S. Mirkin Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens Menopause 20 2013 138 145
36. E.B. Gold, A. Colvin, and N. Avis Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation American Journal of Public Health 96 2006 1226 1235
37. R.E. Williams, L. Kalilani, and D.B. DiBenedetti Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States Climacteric 11 2008 32 43
38. H. Yu, J. Racketa, A.A. Chines, and S. Mirkin Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women Climacteric 16 2013 252 257
39. J.V. Pinkerton, A.A. Chines, J. Racketa, and S. Mirkin Bazedoxifene/conjugated estrogens (BZA/CE): effect on sleep parameters in postmenopausal women Menopause 17 2010 1237 1238
40. J.V. Pinkerton, A.G. Bushmakin, J. Racketa, J.C. Cappelleri, A.A. Chines, and S. Mirkin Direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance Abstract presented at: the 13th World Congress on Menopause June 8-11, Rome, Italy 2011
41. W.H. Utian Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review Health and Quality of Life Outcomes 3 2005 47
42. R.D. Hays, S.A. Martin, A.M. Sesti, and K.L. Spritzer Psychometric properties of the Medical Outcomes Study Sleep measure Sleep Medicine 6 2005 41 44
43. C.D. Hill, S.E. Fehnel, J.D. Bobula, H. Yu, and L.D. McLeod Development and preliminary validation of the Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ) Menopause 14 2007 1047 1055
44. J.V. Pinkerton, A.A. Chines, J. Racketa, and S. Mirkin Menopause-related quality of life and satisfaction in postmenopausal women treated with bazedoxifene/conjugated estrogens (BZA/CE) Menopause 17 2010 1219
45. K.B. Levine, R.E. Williams, and K.E. Hartmann Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women Menopause 15 2008 661 666
46. N. Santoro, and J. Komi Prevalence and impact of vaginal symptoms among postmenopausal women The Journal of Sexual Medicine 6 2009 2133 2142
47. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/pdfs/NOF- ClinicianGuide2009-v7.pdf 2010.
48. S.L. Silverman, A.A. Chines, and D.L. Kendler Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporosis International 23 2012 351 363
49. S. Palacios, S. Silverman, and A.B. Levine Long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled study Presented at: the 13th International Menopause Society World Congress on Menopause June 8-11, Rome, Italy 2011
50. Food and Drug Administration Guidance for Industry. Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation 2003
51. A. Fenton, A. Chines, and S. Mirkin Endometrial safety and bleeding profile of bazedoxifene paired with conjugated estrogens: results from 2 years of therapy Oral presentation at: the 4th Triennial Scientific Meeting of the Asia Pacific Menopause Federation September 26-29, Sydney, Australia 2010
52. P.H. van de Weijer, L.A. Mattsson, and O. Ylikorkala Benefits and risks of long-term low-dose oral continuous combined hormone therapy Maturitas 56 2007 231 248
53. D. Grady, and G.F. Sawaya Discontinuation of postmenopausal hormone therapy American Journal of Medicine 118 2005 163 165
54. C.U. Chae, and C.A. Derby The menopausal transition and cardiovascular risk Obstetrics and Gynecology Clinics of North America 38 2011 477 488
55. M. Lejskova, S. Alusik, Z. Valenta, S. Adamkova, and J. Pitha Natural postmenopause is associated with an increase in combined cardiovascular risk factors Physiological Research 61 2012 587 596
56. C. Christiansen, C.H. Chesnut III, and J.D. Adachi Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis BMC Musculoskeletal Disorders 11 2010 130
57. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
58. J.V. Pinkerton, J.A. Harvey, and K. Pan Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial Obstetrics and Gynecology 121 2013 959 968
59. H.N. Hodis, and W.J. Mack The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 1: comparison of therapeutic efficacy Journal of the American Geriatrics Society 61 2013 1011 1018
60. H.N. Hodis, and W.J. Mack A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent Brain Research 1379 2011 244 252
61. J.H. Pickar, T. MacNeil, and K. Ohleth SERMs: progress and future perspectives Maturitas 67 2010 129 138
62. K.M. Feeley, and M. Wells Hormone replacement therapy and the endometrium Journal of Clinical Pathology 54 2001 435 440
63. J.V. Pinkerton, and S.R. Goldstein Endometrial safety: a key hurdle for selective estrogen receptor modulators in development Menopause 17 2010 642 653
64. R.D. Jackson, J. Wactawski-Wende, and A.Z. LaCroix Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial Journal of Bone and Mineral Research 21 2006 817 828
65. K.C.N. Chang, Y. Wang, P.V. Bodine, S. Nagpal, and B.S. Komm Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens Journal of Steroid Biochemistry and Molecular Biology 118 2010 117 124